{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-145524","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.605441+00:00","generated_at":"2026-05-15T07:01:43.983453+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Stoke Therapeutics appoints Clare Kahn, Ph.D. to Board, increases size to ten","bullets":["Board expanded to 10 directors; Kahn appointed as Class I director effective April 3, 2026.","Kahn receives $45k annual cash retainer and initial option for 30,782 shares (~$724k grant-date value).","Kahn will chair the R&D Committee and serve on the Nominating & Corporate Governance Committee.","Kahn brings 30+ years drug development and regulatory experience from X-VAX, Pfizer, and GSK.","Company is advancing Phase 3 study of zorevunersen for Dravet syndrome."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-145524","json":"https://secwatch.observer/filing/0001193125-26-145524.json","markdown":"https://secwatch.observer/filing/0001193125-26-145524.md","text":"https://secwatch.observer/filing/0001193125-26-145524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526145524/0001193125-26-145524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526145524/d63742d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:01:43.983453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}